CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with standard care for patients with relapsed or refractory multiple myeloma, according to data presented at ASCO Annual Meeting.
Researchers reported a 47% improvement in 1-year PFS with the experimental regimen at the time of a prespecified interim analysis of the randomized phase 3 DREAMM-8 trial.
“We evaluated [this combination] in a pan-Canadian study called the ALGONQUIN study, and we saw very impressive results among patients who were more heavily pretreated than those
